[1]JIAO H, XIAO E, GRAVES DT. Diabetes and its effect on bone and fracture healing.Curr Osteoporos Rep. 2015;13:327-335.
[2]SCHETT G, TEITELBAUM SL. Osteoclasts and arthritis. J Bone Miner Res. 2009,24:1142-1146.
[3]EDWARDS JR, WEIVODA MM. Osteoclasts: malefactors of disease and targets for treatment.Discov Med. 2012;13(70): 201-210.
[4]XIAOW, WANGY, GRAVESDT, et al. Cellular and Molecular Aspects of Bone Remodeling. Frontiers of Oral Biology. 2016; 18:9-16.
[5]王莲莲,郭晓英.破骨细胞分化过程中的信号通路及信号因子的研究[J].中国骨质疏松杂志,2015,21(6):742-748.
[6]CHEN Y, ALMAN BA. Wnt pathway, an essential role in bone regeneration. J Cell Biochem. 2009;106:353-362.
[7]AI-AQL ZS, ALAGL AS, EINHORN TA, et al. Molecular mechanisms controlling bone formation during fracture healing and distraction osteogenesis.J Dent Res.2008;87:107-118.
[8]CHEN G, DENG C, LI YP. TGF-beta and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci.2012; 8:272-288.
[9]XI JC, ZANG HY, MA YZ, et al. The PI3K/AKT cell signaling pathway is involved in regulation of osteoporosis.J Recept Signal Transduct Res. 2015;35(6):640-645.
[10]LIN C, SHAO Y, CAI D, et al. Blocking PI3K/AKT signaling inhibits bone sclerosis in subchondral bone and attenuates post-traumatic osteoarthritis.J Cell Physiol. 2018;233(8):6135-6147.
[11]HUANG S, JIN A. ZIC2 promotes viability and invasion of human osteosarcoma cells by suppressing SHIP2 expression and activating PI3K/AKT pathways.J Cell Biochem. 2018;119(2): 2248-2257.
[12]GU YX,DU J,SI MS,et al. The roles of PI3K/Akt signaling pathway in regulating MC3T3-E1 preosteoblast proliferation and differentiation on SLA and SLActive titanium surfaces. J Biomed Mater Res A.2013; 101: 748-754.
[13]MOON JB, KIM JH, KIM K, et al. Akt induces osteoclast differentiation through regulating the GSK3beta/NFATc1 signaling cascade. J Immunol. 2012;188: 163-169.
[14]ZOU W, YANG S, ZHOU D, et al. Hypoxia enhances glucocorticoid-induced apoptosis and cell cycle arrest via the PI3K/Akt signaling pathway in osteoblastic cells.J Bone Miner Metab. 2015; 33(6):615-624.
[15]FUKUDA A, HIKITA A, WAKEYAMA H, et al. Regulation of osteoclast apoptosis and motility by small GTPase binding protein Rac1. J Bone Miner Res.2005;20: 2245 -2253.
[16]ITO Y, HART JR. Isoform-specific activities of the regulatory subunits of phosphatidylinositol 3-kinases-potentially novel therapeutic targets.Expert Opinion on Therapeutic Targets.2018;22(10): 869-877.
[17]HAWKINS PT, STEPHENS LR. PI3K signalling in inflammation. Biochim Biophys Acta. 2015;1851(6):882-897.
[18]MAYER IA, ARTEAGA CL. The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med.2016; 67: 11-28.
[19]TIAN L, ZHAO Z, XIE L, et al. MiR-361-5p suppresses chemoresistance of gastric cancer cells by targeting FOXM1 via the PI3K/Akt/mTOR pathway. Oncotarge.2017; 9(4): 4886-4896.
[20]TANG H, RONGPING LI, LIANG P, et al. miR-125a inhibits the migration and invasion of liver cancer cells via suppression of the PI3K/AKT/mTOR signaling pathway. Oncol Lett. 2015;10(2): 681-686.
[21]南振华,潘灵辉.布洛芬通过PI3K/Akt/mTOR信号通路调控肝癌QGY- 7703细胞迁移和侵袭的机制[J].肿瘤防治研究,2016,43(12):1035-1038.
[22]ZHANG Y, ZHENG L, DING Y, et al. MiR-20a induces cell radioresistance by activating the PTEN/PI3K/Akt signaling pathway in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2015;92(5): 1132-1140.
[23]于世凤.破骨细胞及其骨吸收调控研究进展[J].中国骨质疏松杂志,2000, 6(1):78-83.
[24]MIRON R J, BOSSHARDT DD. OsteoMacs: Keyplayers around bone biomaterials. Biomaterials.2016;82(3):1-19.
[25]FUJII T, KITAURA H, KIMURA K, et al. IL-4 inhibits TNF-α-mediated osteoclast formation by inhibition of RANKL expression in TNF-α-activated stromal cells and direct inhibition of TNF-α-activated osteoclast precursors via a T-cell-independent mechanism in vivo. Bone.2012,51(4): 771-780.
[26]NEALE SD,SMITH R,WASS JA, et al.Osteoclast differentiation from circulating mononuclear precursors in Paget’s disease is hypersensitive to 1,25-dihydroxyvitamin D 3 and RANKL. Bone. 2000;27(3): 409-416.
[27]HWANG YS, MA GT, PARK KK, et al.Lysophosphatidic acid stimulates osteoclast fusion through OC-STAMP and P2X7 receptor signaling. J Bone Miner Metab. 2014;32(2):110-122.
[28]WANG HUA-BEI.The present research situation of OPG / RANKL / RANK signaling pathway in the bone related diseases.Chinese Journal of Clinical Research.2012;25 (1):80-81.
[29]BALASUBRAMANYAM K, ALTAF M, VARIER RA, et al. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression.J Biol Chem. 2004;279(32): 33716-33726.
[30]LEE SE, CHUNG WJ, KWAK HB, et al. Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. J Biol Chem.2001;276(52): 49343- 49349.
[31]LEE ZH, LEE SE, KIM CW, et al. IL-1alpha stimulation of osteoclast survival through the PI3-kinase /Akt and ERK pathways. J Biochem. 2002;131(1): 161-166.
[32]TOKER A, NEWTON AC. Cellular signaling: pivoting around PDK-1.Cell.2000;103(2):185-188.
[33]CHELLAIAH M,FITZGERALD C,ALVAREZ U,et al.c-Srcis required for stimulation of gelsolin-associatedphosphatidylinositol3-kinase.J Biol Chem. 1998;273(19):11908-11916.
[34]CHELLAIAH M, HRUSKA K. Osteopontin stimulates gelsolin-associated levels and phosphoinositide phosphatidylinositol triphosphate-hydroxyl kinase.Mol Biol Cell. 1996;7(5) :743-753.
[35]LAKKAKORPI PT, WESOLOWSKI G, ZIMOLO Z, et al. Phosphatidylinositol 3-kinase association with the osteoclast cytoskeleton,and its involvement in osteoclast attachment and spreading.Exp Cell Res.1997;237 (2):296-306.
[36]PILKINGTON MF, SIMS SM, DIXON SJ. Dixon.Wortmannin inhibits spreading and chemotaxis of rat osteoclasts in vitro.J Bone Miner Res. 1998;13(4):688-694.
[37]NAKAMURA I, TAKAHASHI N, SASAKI T, et al.Wortmannin,a specific inhibitor of phosphatidylinositol-3 kinase, blocks osteoclastic bone resorption.FEBS Lett.1995;361(1):79-84.
[38]HALL TJ, JEKER H, SCHAUEBLIN M. Schaueblin. Wortmannin, apotentinhibitorofphosphatidylinositol3-kinase, inhibits osteoclastic bone resorption in vitro.Calcif Tissue Int.1995;56(4):336-338.
[39]LEE SE, WOO KM, KIM SY, et al. The phosphatidylinositol 3-kinase,p38,and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone.2002;30(1):71 -77.
[40]LIU Q, SASAKI T, KOZIERADZKI I, et al. SHIP is a negative regulator of growth factor receptormediated PKB/Akt activation and myeloid cell survival. Genes Dev.1999;13:786-791.
[41]TAKESHITA S, NAMBA N, ZHAO JJ, et al. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts.Nat. Med.2002;8: 943-949.
[42]WONG BR, BESSER D, KIM N, et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell.1999;4:1041-1049.
[43]LEE ZH, KIM HH. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun. 2003; 305:211-214.
[44]KIM JY, OH HM, KWAK SC, et al. Purslane suppresses osteoclast differentiation and bone resorbing activity via inhibition of Akt / GSK3β-c-Fos-NFATc1 signaling in vitro and prevents lipopolysaccharide-induced bone loss in vivo.Biol Pharm Bull. 2015; 38(1):66-74.
[45]SUGATANI T, HRUSKA KA. Akt1 /Akt2 and mammalian target of rapamy- cin /Bim play critical roles in osteoclast differentiation and survival,respectively,whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem.2005;280(5): 3583-3589.
[46]KAWAMURA N, KUGIMIYA F, OSHIMA Y, et al.Akt1 in osteoblasts and osteoclasts controls bone remodeling. Plos One.2007;2(10): 1058.
[47]ULICI V, HOENSELAAR KD, AGOSTON H, et al. The role of Akt1 in terminal stages of endochondral bone formation: angiogenesis and ossification.Bone.2009;45: 1133-1145.
[48]PENG XD, XU PZ, CHEN ML, et al.D warfism,impaired skin development, skeletal muscle atrophy,delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev.2003; 17: 1352-1365.
[49]HOSOI H, DILLING MB, HOUGHTON PJ, et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.Cancer Res.1999;59(4): 886-894.
[50]SUGATANI T, ALVAREZ UM, HRUSKA KA. Activin A stimulates IkappaB-alpha/NFka-ppaB and RANK expressio-n for osteoclastdifferentiation,but not AKT survival pathway in osteoclast precursors.J Cell Biochem. 2003;90(1):59-67.
[51]GLANTSCHNIG H, FISHER JE, RESZKA AA, et al. M-CSF,TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase.Cell Death Differ. 2003; 10(10):1165-1177.
[52]ZHAO C, SUN W, ZHANG P, et al. miR-214 promotes osteoclastogenesis by targeting Pten/PI3k/Akt pathway. RNA Biol. 2015;12(3):343-353.
[53]LI M, LUO R, YANG W, et al .miR-363-3p is activated by MYB and regulates osteoporosis pathogenesis via PTEN/PI3K/AKT signaling pathway.In Vitro Cell Dev Biol Anim. 2019;55(5):376-386.
[54]SHAO X, MIAO M, XUE J, et al. The Down-Regulation of MicroRNA -497 Contributes to Cell Growth and Cisplatin Resistance Through PI3K/Akt Pathway in Osteosarcoma. Cell Physiol Biochem.2015; 5(36):2051-2062.
[55]GUNTUR AR, ROSEN CJ. The skeleton: a multi-functional complex organ: new insights into osteoblasts and their role in bone formation: the central role of PI3Kinase.J Endocrinol. 2011;211(2):123-130.
[56]HONG D, CHEN HX, YU HQ, et al.Morphological and proteomic analysis of early stage of osteoblast differentiation in osteoblastic progenitor cells.Exp Cell Res. 2010;316(14):2291-2300.
[57]MUKHERJEE A, ROTWEIN P. Akt promotes BMP2-mediated osteoblast differentiation and bone development. J Cell Sci. 2009; 122(Pt 5):716-726.
[58]ZHANG Z,ZHANG X,ZHAO D,et al.TGF β1 promotes the osteoinduction of human osteoblasts via the PI3K/AKT/mTOR/S6K1 signalling pathway.Mol Med Rep. 2019;19(5):3505-3518.
[59]SUZUKI E, OCHIAI-SHINO H, AOKI H, et al.Akt Activation is Required for TGF-β1-Induced Osteoblast Differentiation of MC3T3-E1 Pre-Osteoblasts.PLoS One. 2014; 9(12): e112566.
[60]GHOSH-CHOUDHURY N, ABBOUD SL, NISHIMURA R, et al. Requirement of BMP-2-induced Phosphatidylinositol 3-Kinase and Akt Serine/Threonine Kinasein Osteoblast Differentiation and Smad-dependent BMP-2Gene Transcription. J Biol Chem. 2002;277(36):33361-33368.
[61]BURGERS TA, HOFFMANN MF, COLLINS CJ, et al .Mice Lacking Pten in Osteoblasts Have Improved Intramembranous and Late Endochondral Fracture Healing.PLoS One. 2013;8(5): e63857.
[62]DUFOUR C, HOLY X, MARIE PJ. Transforming growth factor-beta prevents osteoblast apoptosis induced by skeletal unloading via PI3K/Akt, Bcl-2, and phospho-Bad signaling.Am J Physiol Endocrinol Metab. 2008;294(4):E794-801.
[63]XI JC, ZANG HY, GUO LX, et al . The PI3K/AKT cell signaling pathway is involved in regulation of osteoporosis. J Recept Signal Transduct Res. 2015;35(6):640-645.
[64]DENG S, DAI G, CHEN S, et al . Dexamethasoneinduces osteoblast apoptosis through ROS-PI3K/AKT/GSK3 signaling pathway. Biomed Pharmacother. 2019;110:602-608.
[65]LIAN Z, HAN J, HUANG L, et al. Retraction of: A005, a novel inhibitor of phosphatidylinositol 3-kinase/mammalian target of rapamycin, prevents osteosarcoma-induced osteolysis.Carcinogenesis. 2019; 40(2):e1-e13.
[66]MARTIN SK, GAN ZY, FITTER S, et al .The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma. Leuk Res. 2015;39(3):380-387.
[67]YEON JT, KIM KJ, SON YJ, et al .Idelalisib inhibits osteoclast differentiation and pre-osteoclast migration by blocking the PI3Kδ-Akt-c-Fos/NFATc1 signaling cascade.Arch Pharm Res. 2019; 42(8):712-721.
|